XENCOR,INC. (NASDAQ:XNCR) Files An 8-K Other Events
Item 8.01 Other Events.
On March8, 2019, Xencor,Inc. announced the closing of the Collaboration and License Agreement with Genentech,Inc. and Hoffmann-LaRoche Ltd. in the press release attached hereto as Exhibit99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
|
ExhibitNo. |
Description |
|
99.1 |
Press release dated March8, 2019. |
Xencor Inc Exhibit
EX-99.1 2 a19-6032_1ex99d1.htm EX-99.1 Exhibit 99.1 Xencor Announces Closing of Research Collaboration and License Agreement with Genentech MONROVIA,…
To view the full exhibit click here
About XENCOR,INC. (NASDAQ:XNCR)
Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. Its clinical stage product candidates include XmAb5871, which is being developed for autoimmune disease, and XmAb7195, which is being developed for asthma and allergic diseases. Its oncology product candidates are in preclinical stage, which include XmAb14045 and XmAb13676. In addition to its compounds in clinical development, the Company uses its XmAb technology to create antibody compounds which are licensed to other pharmaceutical and biotechnology companies for further development, which include XmAb5574/MOR208 and XmAb13551.
